{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:44:06Z","timestamp":1791924246591,"version":"4.3.4"},"reference-count":65,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.7722","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T15:11:56Z","timestamp":1650381116000},"page":"e227722","source":"Crossref","is-referenced-by-count":56,"title":["Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events"],"prefix":"10.1001","volume":"5","author":[{"given":"Muhammad Zain","family":"Farooq","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Moffitt Cancer Center, University of South Florida, Tampa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba Ba","family":"Aqeel","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanth","family":"Lingamaneni","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, John H. Stroger Jr, Hospital of Cook County, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayli Carolina","family":"Pichardo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Henry Ford Health System, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleeza","family":"Jawed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ziauddin University Hospital, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Khalid","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shristi Upadhyay","family":"Banskota","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University of Nebraska Medical Center, Lincoln"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingfu","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Mangla","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"issue":"1","key":"zoi220244r1","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy.","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"zoi220244r2","article-title":"How we treat neurological toxicity from immune checkpoint inhibitors.","volume":"4","author":"Spain","year":"2019","journal-title":"ESMO Open"},{"issue":"12","key":"zoi220244r3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"6","key":"zoi220244r4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis.","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"key":"zoi220244r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature.","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"issue":"10","key":"zoi220244r6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11910-018-0877-8","article-title":"Management of brain metastases in the new era of checkpoint inhibition.","volume":"18","author":"Lauko","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"zoi220244r7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020186","article-title":"Virus-based immunotherapy of glioblastoma.","volume":"11","author":"Martikainen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"zoi220244r8","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"zoi220244r9","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"zoi220244r10","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you \u2018take the brakes off\u2019 the immune system.","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"zoi220244r11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"zoi220244r12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors.","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"19","key":"zoi220244r13","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma.","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi220244r14","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi220244r15","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"issue":"8","key":"zoi220244r16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi220244r17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","article-title":"The heterogeneity statistic I2 can be biased in small meta-analyses.","volume":"15","author":"von Hippel","year":"2015","journal-title":"BMC Med Res Methodol"},{"issue":"12","key":"zoi220244r18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11912-019-0859-2","article-title":"Neurologic immune-related adverse events associated with immune checkpoint inhibition.","volume":"21","author":"Pan","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"zoi220244r19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"zoi220244r20","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study.","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"zoi220244r21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/bja\/aet208","article-title":"Neuropathic pain in cancer.","volume":"111","author":"Fallon","year":"2013","journal-title":"Br J Anaesth"},{"issue":"12","key":"zoi220244r22","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"issue":"15","key":"zoi220244r23","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.2165\/00003495-200363150-00003","article-title":"Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.","volume":"63","author":"Verstappen","year":"2003","journal-title":"Drugs"},{"key":"zoi220244r24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3389\/fphys.2017.00134","article-title":"Alteration in taste perception in cancer: causes and strategies of treatment.","volume":"8","author":"Murtaza","year":"2017","journal-title":"Front Physiol"},{"issue":"11","key":"zoi220244r25","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/cncr.v127.11","article-title":"Oral side effects of immune checkpoint inhibitor therapy (ICIT): an analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women\u2019s Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019.","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"zoi220244r26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00520-007-0319-7","article-title":"Self-reported taste and smell changes during cancer chemotherapy.","volume":"16","author":"Bernhardson","year":"2008","journal-title":"Support Care Cancer"},{"issue":"4","key":"zoi220244r27","first-page":"697","article-title":"Taste changes experienced by patients receiving chemotherapy.","volume":"26","author":"Wickham","year":"1999","journal-title":"Oncol Nurs Forum"},{"issue":"1","key":"zoi220244r28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"20","key":"zoi220244r29","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/sim.3964","article-title":"Meta-analysis for rare events.","volume":"29","author":"Cai","year":"2010","journal-title":"Stat Med"},{"issue":"5","key":"zoi220244r30","doi-asserted-by":"publisher","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","article-title":"Real-world evidence in oncology: opportunities and limitations.","volume":"25","author":"Di Maio","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"zoi220244r31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jtho.2019.02.001","article-title":"Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report.","volume":"14","author":"Yang","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"10167","key":"zoi220244r32","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"zoi220244r33","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi220244r34","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10183","key":"zoi220244r35","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"10189","key":"zoi220244r36","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"zoi220244r37","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi220244r38","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"zoi220244r39","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol"},{"issue":"11","key":"zoi220244r40","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.","volume":"19","author":"Barlesi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"19","key":"zoi220244r41","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage iii melanoma.","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi220244r42","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer.","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi220244r43","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"zoi220244r44","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer.","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"10122","key":"zoi220244r45","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"10142","key":"zoi220244r46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"issue":"24","key":"zoi220244r47","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi220244r48","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1158\/1078-0432.CCR-17-0025","article-title":"Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced\/metastatic gastric or gastroesophageal junction cancer.","volume":"23","author":"Bang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"zoi220244r49","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma.","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi220244r50","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage iv or recurrent non-small-cell lung cancer.","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"issue":"30","key":"zoi220244r51","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1200\/JCO.2016.71.7629","article-title":"Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer.","volume":"35","author":"Govindan","year":"2017","journal-title":"J Clin Oncol"},{"key":"zoi220244r52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur J Cancer"},{"issue":"9","key":"zoi220244r53","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10066","key":"zoi220244r54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"10030","key":"zoi220244r55","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"zoi220244r56","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"10027","key":"zoi220244r57","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1\u2013positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"11","key":"zoi220244r58","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"zoi220244r59","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non-small-cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"31","key":"zoi220244r60","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer.","volume":"34","author":"Reck","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"zoi220244r61","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi220244r62","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"7","key":"zoi220244r63","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi220244r64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.","volume":"24","author":"Reck","year":"2013","journal-title":"Ann Oncol"},{"issue":"26","key":"zoi220244r65","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2791294\/farooq_2022_oi_220244_1649859919.21847.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T15:12:03Z","timestamp":1650381123000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2791294"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.7722","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]}}}